Patents by Inventor Claude Laruelle

Claude Laruelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11185520
    Abstract: A composition comprising, as an active principle, a pharmaceutically acceptable salt of elafibranor, characterised in that the pharmaceutically acceptable salt of elafibranor is chosen from at least a salt of choline, of ethanolamine, or of diethanolamine, or of L-lysine, or of piperazine, or of calcium, or of tromethamine. More particularly, one or more embodiments relate to the use of elafibranor salts with a view to improving stability and solubility compared with elafibranor in the basic form thereof. These salts make it possible to establish pharmaceutical formulations in various advantageous forms as intravenous injections or formulations by enteral route having quicker and less variable absorption and consequently better bioavailability.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: November 30, 2021
    Assignee: NASHPHARM
    Inventors: Claude Laruelle, Ludovic Bonnafous
  • Publication number: 20200023067
    Abstract: Drugs derived from elafibranor. One or more embodiments relate more particularly to a composition comprising at least one active principle, wherein the at least one active principle comprises an elafibranor metformin salt. One or more embodiments also relate to a derivative of elafibranor having dual action for treating obesity associated with non-alcoholic steatohepatitis (NASH) and hypertriglyceridaemia.
    Type: Application
    Filed: September 28, 2017
    Publication date: January 23, 2020
    Inventors: Claude LARUELLE, Ludovic BONNAFOUS
  • Publication number: 20190274982
    Abstract: A composition comprising, as an active principle, a pharmaceutically acceptable salt of elafibranor, characterised in that the pharmaceutically acceptable salt of elafibranor is chosen from at least a salt of choline, of ethanolamine, or of diethanolamine, or of L-lysine, or of piperazine, or of calcium, or of tromethamine. More particularly, one or more embodiments relate to the use of elafibranor salts with a view to improving stability and solubility compared with elafibranor in the basic form thereof. These salts make it possible to establish pharmaceutical formulations in various advantageous forms as intravenous injections or formulations by enteral route having quicker and less variable absorption and consequently better bioavailability.
    Type: Application
    Filed: September 28, 2017
    Publication date: September 12, 2019
    Inventors: Claude LARUELLE, Ludovic BONNAFOUS
  • Publication number: 20190247343
    Abstract: A composition comprising as a sole active ingredient fenofibric acid or one of the pharmaceutically acceptable salts thereof for use in the treatment of liver diseases. The field relates to the treatment and prevention of liver diseases, such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis or cirrhosis.
    Type: Application
    Filed: April 13, 2017
    Publication date: August 15, 2019
    Inventors: Claude LARUELLE, Ludovic BONNAFOUS
  • Patent number: 9468662
    Abstract: A PAT nonapeptide of formula EAKSQGGSD (SEQ ID NO: 1) can be used to treat or prevent neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Pharmaceutical compositions containing the PAT nonapeptide can be formulated for administration by parenteral route, including the subcutaneous, intraperitoneal, intravenous or intranasal routes.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: October 18, 2016
    Assignee: ORPHIT
    Inventors: Claude Laruelle, Jamal Temsamani, Frederic Mourlane
  • Patent number: 9427455
    Abstract: The invention refers to the use of the PAT nonapeptide which is a thymuline analog in the treatment of autoimmune diseases, in particular of rheumatoid arthritis and intestinal bowel diseases (IBD) such as the Crohn's disease.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: August 30, 2016
    Assignee: CLL PHARMA
    Inventors: Jamal Temsamani, Claude Laruelle
  • Publication number: 20160074463
    Abstract: A PAT nonapeptide of formula EAKSQGGSD can be used to treat or prevent neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Pharmaceutical compositions containing the PAT nonapeptide can be formulated for administration by parenteral route, including the subcutaneous, intraperitoneal, intravenous or intranasal routes.
    Type: Application
    Filed: November 2, 2015
    Publication date: March 17, 2016
    Inventors: Claude LARUELLE, Jamal TEMSAMANI, Frederic MOURLANE
  • Patent number: 9192654
    Abstract: The invention relates to the use of the PAT nonapeptide in the manufacture of a drug for preventing or treating a neurodegenerative disease such as Alzheimer's disease. The parenteral route of administration is preferable, including the subcutaneous, intraperitoneal, intravenous or intranasal routes. The invention also relates to an injectable formulation containing the PAT nonapeptide which can be administered to patients suffering from a neurodegenerative disease such as Alzheimer's disease.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: November 24, 2015
    Assignee: CLL PHARMA
    Inventors: Jamal Temsamani, Claude Laruelle
  • Patent number: 9029390
    Abstract: The invention relates to non hemolytic compositions containing an antiplatelet agent such as clopidogrel or ticlopidine; these compositions being characterized in that the antiplatelet agent is in the form of free base, and the composition contains at least one hydrophilic non ionic surfactant. The invention relates also a galenic form, a method of preparation of thereof, as well as therapeutic uses of thereof, especially in patients who suffer from undesirable effects related to hemolysis and/or gastrointestinal acidity.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: May 12, 2015
    Assignee: CLL Pharma
    Inventors: Thierry Breul, Claude Laruelle
  • Publication number: 20130116193
    Abstract: The invention relates to the use of the PAT nonapeptide in the manufacture of a drug for preventing or treating a neurodegenerative disease such as Alzheimer's disease. The parenteral route of administration is preferable, including the subcutaneous, intraperitoneal, intravenous or intranasal routes. The invention also relates to an injectable formulation containing the PAT nonapeptide which can be administered to patients suffering from a neurodegenerative disease such as Alzheimer's disease.
    Type: Application
    Filed: July 11, 2011
    Publication date: May 9, 2013
    Applicant: CLL PHARMA
    Inventors: Jamal Temsamani, Claude Laruelle
  • Publication number: 20110123606
    Abstract: The invention relates to non hemolytic compositions containing an antiplatelet agent such as clopidogrel or ticlopidine; these compositions being characterized in that the antiplatelet agent is in the form of free base, and the composition contains at least one hydrophilic non ionic surfactant. The invention relates also a galenic form, a method of preparation of thereof, as well as therapeutic uses of thereof, especially in patients who suffer from undesirable effects related to hemolysis and/or gastrointestinal acidity.
    Type: Application
    Filed: June 15, 2009
    Publication date: May 26, 2011
    Inventors: Thierry Breul, Claude Laruelle
  • Publication number: 20110098223
    Abstract: The invention refers to the use of the PAT nonapeptide which is a thymuline analog in the treatment of autoimmune diseases, in particular of rheumatoid arthritis and intestinal bowel diseases (IBD) such as the Crohn's disease.
    Type: Application
    Filed: April 15, 2009
    Publication date: April 28, 2011
    Inventors: Jamal Temsamani, Claude Laruelle
  • Publication number: 20040143012
    Abstract: The invention concerns a method for stabilising particle size distribution of a powdery active principle, when the latter is dispersed in a liquid. Said method is characterised in that it consists in dispersing said active principle in a glycol ether or a mixture of glycol ethers. The invention also concerns the uses of said method and, in particular for pharmaceutical compositions and galenic forms comprising a retinoid as active principle, and suited for providing the latter with improved bioavailability (suprabioavailability) after oral administration.
    Type: Application
    Filed: June 10, 2003
    Publication date: July 22, 2004
    Inventors: Rene Gimet, Claude Laruelle, Dominique Toselli
  • Publication number: 20040052824
    Abstract: The invention concerns novel pharmaceutical compositions capable of comprising micelles containing at least a very lipophilic principle, enabling to enhance bioavailability of active principles insoluble in aqueous solvents called MIDDS® (Micellar Improved Drug Delivery Solutions).
    Type: Application
    Filed: June 25, 2003
    Publication date: March 18, 2004
    Inventors: Marie-Line Abou Chacra-Vernet, Claude Laruelle, Dominique Toselli
  • Patent number: 6669957
    Abstract: The invention relates to pharmaceutical dosage forms with rapid disintegration in the mouth and to their process of preparation. These pharmaceutical dosage forms comprise at least one active principle dispersed in a mixture of excipients and are characterized in that the mixture of excipients comprises at least one weakly compressible diluting agent other than trehalose and a copolymer of 1-vinylpyrrolidin-2-one and of vinyl acetate. Applications: oral administration of a great many active principles (analgesics, antispasmodics, agents used in gastroenterology, agents for combating motion sickness, antimigraines, &bgr;-blockers, antihistaminics, antibiotics or antibacterials, antivertigos, hypnotics, and the like).
    Type: Grant
    Filed: September 5, 2001
    Date of Patent: December 30, 2003
    Assignee: CLL Pharma
    Inventors: Claude Laruelle, Noël Zakarian, René Gimet, Dominique Toselli
  • Patent number: 6605301
    Abstract: The invention relates to dispersible tablets containing macrolides as active ingredients either on their own or associated with other active ingredients, in addition to a method for the production thereof. The dispersible tablets are characterized in that the macrolide is chosen from a group that is made up of pristinamycin, azithromycin, roxithromycin, clarithromycin and spiramycin, and is present in a basic form in proportions ranging from 20-60% of the total weight of said tablets. The dispersible tablets are also characterized in that they contain at least one disintegrator in proportions ranging from 1-25% of the total weight of said tablets in addition to at least one sweetening agent.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: August 12, 2003
    Assignee: CCL Pharma
    Inventors: Noël Zakarian, René Gimet, Claude Laruelle, Dominique Toselli
  • Publication number: 20020061333
    Abstract: The invention relates to dispersible tablets containing macrolides as active ingredients either on their own or associated with other active ingredients, in addition to a method for the production thereof. The dispersible tablets are characterized in that the macrolide is chosen from a group that is made up of pristinamycin, azithromycin, roxithromycin, clarithromycin and spiramycin, and is present in a basic form in proportions ranging from 20-60% of the total weight of said tablets. The dispersible tablets are also characterized in that they contain at least one disintegrator in proportions ranging from 1-25% of the total weight of said tablets in addition to at least one sweetening agent.
    Type: Application
    Filed: September 28, 2001
    Publication date: May 23, 2002
    Inventors: Noel Zakarian, Rene Gimet, Claude Laruelle, Dominique Toselli
  • Patent number: 5827536
    Abstract: Soluble fenofibrate (Rec. INN) formulations exhibiting a significantly improved bioavailability after oral administration ("superbioavailability"), a process for their production and medicaments comprising these formulations. The said fenofibrate pharmaceutical dosage formulations essentially contain fenofibrate in solution in a solubilizing agent consisting of a non-ionic surfactant, diethylene glycol monoethyl ether (DGME).
    Type: Grant
    Filed: July 25, 1996
    Date of Patent: October 27, 1998
    Assignee: CLL Pharma
    Inventor: Claude Laruelle
  • Patent number: 5527523
    Abstract: Hydroquinone amino-acid esters having formula (I), pharmaceutical or cosmetic compositions containing them, particularly dermatological compositions having pigment-removing activity, and the pharmaceutical, cosmetic or aesthetic uses thereof. The preparation of these novel hydroquinone esters from natural amino-acid derivatives is also described.
    Type: Grant
    Filed: October 13, 1992
    Date of Patent: June 18, 1996
    Assignee: Virbac S.A.
    Inventors: Claude Laruelle, Bernard Raynier, Guy Derrieu
  • Patent number: 5310757
    Abstract: Derivatives of 3,3,5-trimethylcyclohexanol methyl-2-propionate, preparation method, and therapeutical compositions containing them. Such derivatives have general formula (I).
    Type: Grant
    Filed: January 16, 1992
    Date of Patent: May 10, 1994
    Assignee: Panmedica
    Inventors: Claude Laruelle, Marcel Lepant